Tumor Biology

, Volume 37, Issue 3, pp 3757–3764 | Cite as

ROCK inhibitor Y-27632 inhibits the growth, migration, and invasion of Tca8113 and CAL-27 cells in tongue squamous cell carcinoma

  • Zhi-Ming Wang
  • Dong-Sheng Yang
  • Jie Liu
  • Hong-Bo Liu
  • Ming Ye
  • Yu-Fei Zhang
Original Article


The objective of this study is to determine the effects of Rho-associated coiled-coil containing protein kinase (ROCK) inhibitor Y-27632 on the growth, invasion, and migration of Tca8113 and CAL-27 cells in tongue squamous cell carcinoma (TSCC). The methods of the study are as follows: After being routinely cultured for 24 h, Tca8113 and CAL-27 cells were treated with Y-27632 solution. The morphological change of Y-27632-treated cells was observed under an optical microscope and an inverted microscope; MTT assay was performed to measure the optical density (OD) of cells and calculate cell growth inhibition rate; the change of apoptosis was detected by AnnexinV-FITC/PI assay; cell invasion and migration were measured by Transwell assay. The results were as follows: (1) With increasing concentration of Y-27632, cell morphology changed and cell apoptosis appeared; (2) MTT assay showed that inhibition effect of Y-27632 on Tca8113 and CAL-27 cells was enhanced with increasing concentrations and time (all P < 0.01); (3) Apoptosis showed that, compared with controls, the number of apoptosis cells in experimental groups was significantly increased (all P < 0.01). Apoptosis rate was elevated with increasing concentrations of Y-27632; (4) Transwell assay showed, after a treatment with Y-27632, the number of migrated and invaded Tca8113 and CAL-27 cells in each group was statistically different (all P < 0.01); compared with controls, the number of migrated cell in groups treated with Y-27632 was decreased and less Tca8113 and CAL-27 cells in experimental groups passed through polycarbonate membrane (all P < 0.05). The study concludes that Y-27632 can inhibit the growth, invasion, and migration of Tca8113 and CAL-27 cells, suggesting that Y-27632 may be therapeutically useful in TSCC.


ROCK inhibitor Y-27632 Tca8113 CAL-27 Tongue squamous cell carcinoma Cell growth Cell invasion Cell migration 



This study was supported by the Liaoning Science and Technology Project (No. 2012225100) and Natural Science Foundation of Liaoning Province (No. 20102286).

Conflicts of interest



  1. 1.
    Eslami A, Miyaguchi K, Mogushi K, Watanabe H, Okada N, Shibuya H, et al. Parvb overexpression increases cell migration capability and defines high risk for endophytic growth and metastasis in tongue squamous cell carcinoma. Br J Cancer. 2015;112(2):338–44.CrossRefPubMedGoogle Scholar
  2. 2.
    Ding X, Zhang N, Cai Y, Li S, Zheng C, Jin Y, et al. Down-regulation of tumor suppressor mtus1/atip is associated with enhanced proliferation, poor differentiation and poor prognosis in oral tongue squamous cell carcinoma. Mol Oncol. 2012;6(1):73–80.CrossRefPubMedGoogle Scholar
  3. 3.
    Makinen LK, Atula T, Hayry V, Jouhi L, Datta N, Lehtonen S, et al. Predictive role of toll-like receptors 2, 4, and 9 in oral tongue squamous cell carcinoma. Oral Oncol. 2015;51(1):96–102.CrossRefPubMedGoogle Scholar
  4. 4.
    Wang J, Liu XH, Yang ZJ, Xie B, Zhong YS. The effect of ROCK-1 activity change on the adhesive and invasive ability of y79 retinoblastoma cells. BMC Cancer. 2014;14:89.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Narumiya S, Tanji M, Ishizaki T. Rho signaling, ROCK and mdia1, in transformation, metastasis and invasion. Cancer Metastasis Rev. 2009;28(1-2):65–76.CrossRefPubMedGoogle Scholar
  6. 6.
    Liu S. The ROCK signaling and breast cancer metastasis. Mol Biol Rep. 2011;38(2):1363–6.CrossRefPubMedGoogle Scholar
  7. 7.
    Wong CC, Wong CM, Tung EK, Man K, Ng IO. Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion. Hepatology. 2009;49(5):1583–94.CrossRefPubMedGoogle Scholar
  8. 8.
    Jiang L, Liu X, Kolokythas A, Yu J, Wang A, Heidbreder CE, et al. Downregulation of the Rho gtpase signaling pathway is involved in the microRNA-138-mediated inhibition of cell migration and invasion in tongue squamous cell carcinoma. Int J Cancer. 2010;127(3):505–12.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Vigil D, Kim TY, Plachco A, Garton AJ, Castaldo L, Pachter JA, et al. ROCK1 and ROCK2 are required for non-small cell lung cancer anchorage-independent growth and invasion. Cancer Res. 2012;72(20):5338–47.CrossRefPubMedGoogle Scholar
  10. 10.
    Ohta T, Takahashi T, Shibuya T, Amita M, Henmi N, Takahashi K, et al. Inhibition of the Rho/ROCK pathway enhances the efficacy of cisplatin through the blockage of hypoxia-inducible factor-1alpha in human ovarian cancer cells. Cancer Biol Ther. 2012;13(1):25–33.CrossRefPubMedGoogle Scholar
  11. 11.
    Guo Y, Liu Q, Yang Y, Guo X, Lian R, Li S, et al. The effects of ROCK inhibitor y-27632 on injectable spheroids of bovine corneal endothelial cells. Cell Reprogram. 2015;17(1):77–87.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Bueno C, Montes R, Menendez P. The ROCK inhibitor Y-27632 negatively affects the expansion/survival of both fresh and cryopreserved cord blood-derived cd34+ hematopoietic progenitor cells: Y-27632 negatively affects the expansion/survival of cd34 + hspcs. Stem Cell Rev. 2010;6(2):215–23.CrossRefPubMedGoogle Scholar
  13. 13.
    Zhang J, He X, Ma Y, Liu Y, Shi H, Guo W, et al. Overexpression of ROCK1 and ROCK2 inhibits human laryngeal squamous cell carcinoma. Int J Clin Exp Pathol. 2015;8(1):244–51.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Nakamura K, Yoshimura A, Kaneko T, Sato K, Hara Y. ROCK inhibitor y-27632 maintains the proliferation of confluent human mesenchymal stem cells. J Periodontal Res. 2014;49(3):363–70.CrossRefPubMedGoogle Scholar
  15. 15.
    Abdel-Magid AF. Rho kinase inhibitors: potentially versatile therapy for the treatment of cardiovascular diseases and more. ACS Med Chem Lett. 2015;6(4):371–2.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Xu XT, Song QB, Yao Y, Ruan P, Tao ZZ. Inhibition of RhoA/ROCK signaling pathway promotes the apoptosis of gastric cancer cells. Hepatogastroenterology. 2012;59(120):2523–6.PubMedGoogle Scholar
  17. 17.
    Wang L, Xue L, Yan H, Li J, Lu Y. Effects of ROCK inhibitor, y-27632, on adhesion and mobility in esophageal squamous cell cancer cells. Mol Biol Rep. 2010;37(4):1971–7.CrossRefPubMedGoogle Scholar
  18. 18.
    Coleman ML, Densham RM, Croft DR, Olson MF. Stability of p21waf1/cip1 cdk inhibitor protein is responsive to RhoA-mediated regulation of the actin cytoskeleton. Oncogene. 2006;25(19):2708–16.CrossRefPubMedGoogle Scholar
  19. 19.
    Ishizaki T, Uehata M, Tamechika I, Keel J, Nonomura K, Maekawa M, et al. Pharmacological properties of y-27632, a specific inhibitor of Rho-associated kinases. Mol Pharmacol. 2000;57(5):976–83.PubMedGoogle Scholar
  20. 20.
    Yang X, Di J, Zhang Y, Zhang S, Lu J, Liu J, et al. The Rho-kinase inhibitor inhibits proliferation and metastasis of small cell lung cancer. Biomed Pharmacother. 2012;66(3):221–7.CrossRefPubMedGoogle Scholar
  21. 21.
    Schofield AV, Steel R, Bernard O. Rho-associated coiled-coil kinase (ROCK) protein controls microtubule dynamics in a novel signaling pathway that regulates cell migration. J Biol Chem. 2012;287(52):43620–9.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Jeong KJ, Park SY, Cho KH, Sohn JS, Lee J, Kim YK, et al. The Rho/ROCK pathway for lysophosphatidic acid-induced proteolytic enzyme expression and ovarian cancer cell invasion. Oncogene. 2012;31(39):4279–89.CrossRefPubMedGoogle Scholar
  23. 23.
    Wyckoff JB, Pinner SE, Gschmeissner S, Condeelis JS, Sahai E. ROCK- and myosin-dependent matrix deformation enables protease-independent tumor-cell invasion in vivo. Curr Biol. 2006;16(15):1515–23.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Zhi-Ming Wang
    • 1
  • Dong-Sheng Yang
    • 1
  • Jie Liu
    • 2
  • Hong-Bo Liu
    • 3
  • Ming Ye
    • 1
  • Yu-Fei Zhang
    • 1
  1. 1.Department of Oral and Maxillofacial SurgeryShengjing Hospital of China Medical UniversityShenyangChina
  2. 2.Experimental Technology Center of China Medical UniversityShenyangChina
  3. 3.Department of Statistics, School of Public HealthChina Medical UniversityShenyangChina

Personalised recommendations